{"title": "Sanaria's PFSPZ vaccine achieves durable protection against heterologous malaria infection in a clinical trial", "text": "", "article_link": null, "url": "http://www.eurekalert.org/pub_releases/2017-02/n-spv021917.php", "region": "namerica", "source_link": null, "funder": "", "meeting": "", "institution": "newsPRos", "keywords": ["Medicine/Health", " Clinical Trials", " Immunology/Allergies/Asthma", " Vaccines", " Infectious/Emerging Diseases"], "journal": "Proceedings of the National Academy of Sciences", "description": "In a PNAS report published today, 'Sanaria's PfSPZ Vaccine Achieves Durable Protection Against Heterologous Malaria Infection in a Clinical Trial,' investigators from NIAID, NIH and the U. Maryland found that three doses of Sanaria\u00ae PfSPZ vaccine provided protection in clinical trial subjects who were exposed to a malaria strain different than the vaccine strain eight months after the last dose of vaccine. 'An enormously important finding,' says world-renowned vaccinologist Dr. Stanley Plotkin.", "date": "Mon, 20 Feb 2017 05:00:00 GMT"}